Key facts
- Endoriz’s last known valuation is $910K (Dec 2024).
- It has raised $50K; the latest was Early Stage VC ($50K) in Dec 2024.
- Notable investors include GU Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Endoriz
- ·The full record, as it builds
Funding rounds
No funding rounds for Endoriz are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Endoriz
Operator of a hormone replacement therapies company based in Gothenburg, Sweden. The company provides oral modified-release triiodothyronine, enabling healthcare professionals to treat patients suffering from thyroid hormone deficiency.
- Sector
- Healthcare
- HQ
- Gothenburg, Sweden
- Founded
- 2021
- Website
- endorizpharma.com/
- Ownership
- Privately Held (backing)
Endoriz doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Endoriz shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Endoriz in its N-PORT filings yet. We sweep new filings monthly.